A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams

Inclusion criteria Participants must meet all the following inclusion criteria to be eligible to participate in this study: 1. Participants have voluntarily signed the informed consent form; 2. 18 years of age or older; 3. Current injecting drug use (previous month); 4. HCV RNA positive participants commencing treatment must be eligible to initiate therapy with Sofosbuvir/Velpatasvir; and 5. In the opinion of the Investigator, the participant is suitable for NSP-based HCV treatment delivery. Exclusion criteria 1\) For HCV RNA positive participants commencing treatment: 1. Any clinically significant condition or history known to contraindicate the use of Sofosbuvir/Velpatasvir or would not be suitable for management within a NSP-based treatment setting; 2. Any contraindicated medication in the Sofosbuvir/Velpatasvir product information; 3. Has previous HCV DAA treatment experience 4. Has a fibroscan score \> 12.5 Kpa 5. HIV co-infection 6. HBV co-infection 7. Is female and is pregnant or breastfeeding 8. Is unable or unwilling to provide informed consent or abide by the requirements of the study.